Topic
Topic
Phase 3 extension data show denifanstat, an oral fatty acid synthase inhibitor, sustained acne improvement through 52 weeks — the longest durability readout for the agent to date.
Denifanstat, an investigational oral acne therapy, showed deeper results through 52 weeks of treatment in data presented at the 2…
Denifanstat, an oral FASN inhibitor, sustained acne lesion reductions through 52 weeks in a Phase 3 open-label extension, per Der…
A Cureus psychodermatological review links digital skincare marketing to self-experimentation and poor adherence in acne vulgaris…
